Skip to content

4 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Real-world effectiveness and safety of lurbinectedin in previously treated small cell lung cancer: results from Jazz EMERGE 402.

BACKGROUND In extensive-stage small cell lung cancer (ES-SCLC), lurbinectedin is approved for first-line maintenance treatment with atezolizumab and as monotherapy following disease progression, but prospective real-world data on its use are lacking. METHODS Jazz EMERGE 402 was a prospective, observational, phase 4 t...

F. Badin, Philip E. Lammers, Geoffrey Liu et al. · 0 citations
Review Open access Oct 2026

Nivolumab and Cabozantinib in People with HIV and Advanced Solid Tumors: A Pilot Trial and Systematic Review.

BACKGROUND People living with HIV (PWH) are underrepresented in immune checkpoint inhibitor (ICI) and targeted therapy trials, despite a growing burden of malignancies. Cabozantinib may remodel the tumor microenvironment by reducing immunosuppressive myeloid populations and enhancing cytotoxic T-cell infiltration, ther...

Hai-Ying Cheng, Ece Cali, Mumtu Lalla et al. · 0 citations
Open access Aug 2026

Ribonucleotide Reductase Inhibition Triggers Ferroptosis in Genetically Defined Subsets of Non–Small Cell Lung Cancer

Abstract Non–small cell lung cancer (NSCLC) is responsible for the majority of cancer-related mortality worldwide. Lung adenocarcinoma is the most common NSCLC subtype. Despite advances in targeted therapies, treatment resistance remains a critical challenge. Ribonucleotide reductase (RNR), a crucial enzyme in deoxyrib...

Utsav Sen, Dalia Natour, Subhamoy Chakraborty et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.